470 related articles for article (PubMed ID: 31369115)
21. Vancomycin plus piperacillin/tazobactam and acute kidney injury risk: A review of the literature.
Covert KL; Knoetze D; Cole M; Lewis P
J Clin Pharm Ther; 2020 Dec; 45(6):1253-1263. PubMed ID: 32810312
[TBL] [Abstract][Full Text] [Related]
22. The concomitant use of vancomycin and piperacillin-tazobactam is associated with acute kidney injury (AKI) in extremely low birth weight infants (ELBW).
Al-Jebawi Y; Karalic K; Shekhawat P; Mhanna MJ
J Neonatal Perinatal Med; 2022; 15(2):303-309. PubMed ID: 34864693
[TBL] [Abstract][Full Text] [Related]
23. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
[TBL] [Abstract][Full Text] [Related]
24. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
Rutter WC; Burgess DS
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712661
[TBL] [Abstract][Full Text] [Related]
25. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
Aslan AT; Pashayev T; Dağ O; Akova M
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.
Mousavi M; Zapolskaya T; Scipione MR; Louie E; Papadopoulos J; Dubrovskaya Y
Pharmacotherapy; 2017 Mar; 37(3):379-385. PubMed ID: 28079263
[TBL] [Abstract][Full Text] [Related]
27. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis.
Chen XY; Xu RX; Zhou X; Liu Y; Hu CY; Xie XF
Int Urol Nephrol; 2018 Nov; 50(11):2019-2026. PubMed ID: 29752626
[TBL] [Abstract][Full Text] [Related]
28. Lowered Risk of Nephrotoxicity through Intervention against the Combined Use of Vancomycin and Tazobactam/Piperacillin: A Retrospective Cohort Study.
Oda K; Hashiguchi Y; Katanoda T; Nakata H; Jono H; Saito H
Microbiol Spectr; 2021 Sep; 9(1):e0035521. PubMed ID: 34346742
[TBL] [Abstract][Full Text] [Related]
29. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.
Gomes DM; Smotherman C; Birch A; Dupree L; Della Vecchia BJ; Kraemer DF; Jankowski CA
Pharmacotherapy; 2014 Jul; 34(7):662-9. PubMed ID: 24753221
[TBL] [Abstract][Full Text] [Related]
30. Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function.
Jeon N; Staley B; Klinker KP; Hincapie Castillo J; Winterstein AG
Int J Antimicrob Agents; 2017 Jul; 50(1):63-67. PubMed ID: 28522340
[TBL] [Abstract][Full Text] [Related]
31. Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review.
Blair M; Côté JM; Cotter A; Lynch B; Redahan L; Murray PT
Am J Nephrol; 2021; 52(2):85-97. PubMed ID: 33735856
[TBL] [Abstract][Full Text] [Related]
32. Evaluating and Mitigating Risk of Acute Kidney Injury with the Combination of Vancomycin and Piperacillin-Tazobactam in Children.
Tillman EM; Goldman JL
Paediatr Drugs; 2021 Jul; 23(4):373-380. PubMed ID: 34235634
[TBL] [Abstract][Full Text] [Related]
33. Risk factors for acute kidney injury in vancomycin and piperacillin/tazobactam combination therapy: A retrospective study.
Yamashita Y; Kawaguchi H; Yano T; Sakurai N; Shibata W; Oshima K; Imai T; Yamada K; Nakamura Y; Nagayama K; Kakeya H
J Infect Chemother; 2021 Nov; 27(11):1614-1620. PubMed ID: 34366231
[TBL] [Abstract][Full Text] [Related]
34. Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.
Okada N; Chuma M; Azuma M; Nakamura S; Miki H; Hamano H; Goda M; Takechi K; Zamami Y; Abe M; Ishizawa K
Eur J Clin Pharmacol; 2019 Dec; 75(12):1695-1704. PubMed ID: 31511938
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
[TBL] [Abstract][Full Text] [Related]
36. Incidence of Nephrotoxicity Among Pediatric Patients Receiving Vancomycin With Either Piperacillin-Tazobactam or Cefepime: A Cohort Study.
Cook KM; Gillon J; Grisso AG; Banerjee R; Jimenez-Truque N; Phillips EJ; Van Driest SL
J Pediatric Infect Dis Soc; 2019 Jul; 8(3):221-227. PubMed ID: 29590376
[TBL] [Abstract][Full Text] [Related]
37. Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children.
Joyce EL; Kane-Gill SL; Priyanka P; Fuhrman DY; Kellum JA
J Am Soc Nephrol; 2019 Nov; 30(11):2243-2251. PubMed ID: 31501354
[TBL] [Abstract][Full Text] [Related]
38. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
Tookhi RF; Kabli NA; Huntul MA; Thabit AK
Intern Emerg Med; 2021 Jun; 16(4):975-979. PubMed ID: 33439417
[TBL] [Abstract][Full Text] [Related]
39. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
[TBL] [Abstract][Full Text] [Related]
40. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
